Theralase’s Photo Dynamic Compound Produces “Anti-cancer Memory Response”

Theralase Technologies Inc. (TSXV:TLT) announced that via new preclinical research it has further validated its Photo Dynamic Compound’s ability to destroy a primary-host tumor. Further, after repeated exposure to the same cancer, animals have been shown to be immune.

As quoted in the press release:

In the latest research completed in November 2014, mice were again treated according to the March 2012 protocol and all of the mice who received the initial Photo Dynamic Therapy (‘PDT’) were successfully treated and remained cancer free. These mice were then re-injected with an equal number of colon cancer cells 20 days later and with no further treatment intervention none of these mice demonstrated tumour regrowth. This confirms and further validates an ability to destroy the primary tumour and strongly suggests protection of the animal via the immune system leading to a short-term immune-mediated ‘memory response’.

Dr. Arkady Mandel, chief scientific operator at Theralase, commented:

Our primary focus since the initial findings of the PDT memory response in May 2014 has been to further understand and validate this phenomenal effect. Our research program has achieved this mandate by demonstrating that Theralase’s NIR PDT destroys the primary tumour and suggests a short term memory response, even when the animal is further challenged with a new round of cancer cells 20 days later, thus preventing the animal from developing cancer. Our latest research suggests that our original hypothesis that ‘memory cells’, such as memory T lymphocytes, part of the immune system, may be reprogrammed to ‘search and destroy’ the threat posed by cancer cells. This is a very important step toward our long-term goal of developing an affordable and practical vaccine to prevent cancer recurrence.

Click here to read the full Theralase Technologies Inc. (TSXV:TLT) press release.